Objective:

To report the first documented case of successful compassionate use of topical cidofovir 0.5% in severe Clade Ib mpox keratitis unresponsive to trifluridine.

Approach:

Key Findings:

• The patient had severe keratitis with persistent epithelial defects and stromal haze despite treatment with trifluridine.
• Topical cidofovir was administered after trifluridine failed to improve the condition.

Interpretation:

The case highlights the potential role of cidofovir in treating mpox keratitis when standard treatments are ineffective.

Limitations:

• This is a single case report, limiting generalizability.
• No long-term follow-up data on the efficacy and safety of cidofovir in this context are provided.

Conclusion:

Topical cidofovir may be a viable treatment option for severe mpox keratitis, warranting further investigation.

Source

Based on findings from:

Patient with longstanding mpox keratitis successfully treated with topical Cidofovir 0.5% eye drops: a case report

Otiti-Sengeri, Juliet, Mugisha, Derrick, Ngoma, Deogratias Badeseke, Lusobya, Rebecca Claire, Atukunda, Immaculate, Colebunders, Robert. Bmc Ophthalmology, 2026.

https://link.springer.com/article/10.1186/s12886-026-04930-6

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.